For research and educational purposes only. Not medical advice.
Retatrutide Reference
Educational, not medical advice reference for Retatrutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also know…
Reference summary
Lilly announced Phase 3 data in 2026, but pepSmart displays retatrutide only as trial-context educational content.
- Categories
- GLP-1, Fat Loss
- Aliases
- LY3437943, GIP/GLP-1/glucagon receptor agonist
- Evidence posture
- human — Human trial data exist, but the product remains investigational.
- Regulatory status
- Investigational. Retatrutide has no FDA-approved dose and FDA states retatrutide cannot be used in compounding under federal law.
- Content review status
- investigational verified